Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN versus FARXIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN versus FARXIGA.
EMPAGLIFLOZIN vs FARXIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
10 mg orally once daily, with or without food; may increase to 25 mg once daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours (range 10-18 h) in patients with T2DM; supports once-daily dosing.
Clinical Note
moderateEmpagliflozin + Gatifloxacin
"Empagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateEmpagliflozin + Rosoxacin
"Empagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateEmpagliflozin + Levofloxacin
"Empagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateEmpagliflozin + Trovafloxacin
"Empagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Renal (54% as unchanged drug) and fecal (41% as unchanged drug or metabolites); biliary excretion is minimal.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor